Loading company…
Nomic Bio provides high-throughput proteomics services using its nELISA platform.
Nomic Bio provides proteomics services through nELISA, a DNA nanotechnology platform for profiling approximately 275 cytokines. It serves research institutions and pharmaceutical companies conducting drug discovery and disease research. Founded in 2018, the company is based in Montreal, Canada. In September 2024, it raised USD 42.00 mn in Series B funding, with Amplitude and Avant Bio among the investors.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in